Metagenomi Therapeutics, Inc. - 10-Q Filing
Metagenomi Therapeutics filed its quarterly report for the period ended March 31, 2026, disclosing financial results and operational updates. The filing outlines ongoing collaborations such as with Ionis Pharmaceuticals under a license agreement effective through January 1, 2028, and mentions equity transactions including preferred stock investments from Vittoria Investment. It also references the issuance of restricted stock units (RSUs) to executives like Brian C Thomas, Ph.D., during Q1 2026.
Tickers: $MGX